Recently, Tianjin Jin Yao Pharma Co., Ltd., a subsidiary of the group, officially changed its name to Tianjin Pharma Heping (Tianjin) Pharmaceutical Co., Ltd., the company is referred to as Tianjin Pharma Heping.

Tianjin Pharma Heping (Tianjin) Pharmaceutical Co., Ltd.(formerly Jin Yao Pharma) was established in November 2010. It is a key enterprise in the biomedical industry chain in the city of Tianjin and a national production base for emergency rescue drugs and small varieties of drugs (drugs in short supply). With the purpose of safeguarding human health, meeting social needs as its own responsibility, and relying on advanced science and technology, the company specializes in the research and development, production and sales of hormone, amino acid drugs, cardiovascular and cerebrovascular, anti-tumor, respiratory and other preparations.

R&D Center: The Company has successively won the qualifications and honorary titles of National High-tech Enterprise, National Special Support Enterprise for Quality Improvement and Efficiency Improvement, the Science and Technology Leading Enterprise of Tianjin, the Specialized and New Enterprise of Tianjin, the Enterprise Technology Center of Tianjin, the Key Laboratory of Tianjin, the Green Factory of Tianjin, and the Advanced Foreign-Invested Enterprise of Tianjin. It has passed the implementation of the integrated management system and multiple ISO international certifications in environment, energy and safety management.

Production workshop: The Company has five modern production workshops, more than 20 fully automatic production lines, more than 100 sets of advanced production equipment domestically and internationally, and has built SCADA, MES, laboratory LIMS, logistics and warehousing LMIS, ERP, CRM, SRM, EHR, etc. Information systems achieve deep integration of automation equipment, intelligent software and integrated systems, and have domestic leading production capabilities and production levels. The product structure is scientific and complete. It now has 220 product approval numbers for 17 dosage forms including injections, ointments, creams, hard capsules, pills, tablets, freeze-dried powder injections, infusions, eye drops, and inhalation preparations. It has the characteristics of wide treatment fields and product serialization.

Quality Inspection Center: The Company has always adhered to the innovative development strategy and carried out new product development, consistency evaluation and international registration around its core advantages to comprehensively enhance product market competitiveness. In recent years, 8 new products have obtained the Approval for Drug Production and Registration issued by National Medical Products Administration, 13 varieties have passed consistency evaluation, and 5 products have passed FDA certification. The key product, methylprednisolone sodium succinate for injection, has become the first sterile lyophilized powder injection in northern China to obtain the U.S. ANDA approval number. The Company has also become the first manufacturer of sterile steroid hormone preparations in China to pass FDA certification. It is a milestone for the biomedical industry of Tianjin.

The Company will base itself on the new development stage, implement new development concepts, integrate into the new development pattern, give full play to the advantages of complete varieties of emergency rescue drugs, and create a production base for all varieties of emergency rescue drugs; highlight the characteristics of comprehensive dosage forms and complete systems, and create a domestic and international CDMO base; relying on the advantages of linkage development of raw materials and preparations, we will create a production base for steroid hormone and amino acid preparations, and biologics. While developing rapidly, we will earnestly fulfill our social responsibilities, help the crisis and rescue the needy, dedicate our love, and contribute to the development of China's national pharmaceutical industry.